Akrivia Health utilizes AI-powered natural language processing to analyze the world's largest dataset of de-identified psychiatric records, facilitating real-world evidence generation and clinical trial optimization for mental health and dementia research. By improving patient recruitment and study feasibility, the platform addresses the high costs and lengthy timelines associated with clinical trials in these critical areas.
Funding
$9.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Clinical trials for mental health and dementia treatments face challenges due to high costs, lengthy timelines, and difficulties in patient recruitment and study feasibility. Traditional methods struggle to efficiently leverage the vast amounts of unstructured data within psychiatric records.
Solution
Akrivia Health offers an AI-powered platform that analyzes a large dataset of de-identified psychiatric records to accelerate real-world evidence generation and optimize clinical trials for mental health and dementia research. The platform uses natural language processing (NLP) to extract and structure data from clinical notes, transforming unstructured information into actionable insights. By linking healthcare organizations with pharmaceutical and biotechnology companies, Akrivia Health facilitates R&D strategy execution, revenue generation, and improved trial efficiencies. The platform also supports study feasibility analysis, patient re-identification for enrollment, and enhanced patient and site recruitment and retention.
Target Audience
The primary target audience includes pharmaceutical companies, biotechnology companies, healthcare organizations, and research institutions involved in mental health and dementia research and drug development.
Features
- AI-powered NLP to process and structure unstructured data from de-identified psychiatric records.
- Access to a large repository of real-world data in dementia and psychiatric conditions, updated regularly.
- Clinical Trial Optimization module to link healthcare organizations with pharmaceutical and biotechnology companies.
- Study Feasibility analysis to model, compare, and optimize scenarios for faster decision-making.
- Patient Re-Identification service to enroll pre-defined patient cohorts into clinical trials.
- Analytics tools to build custom charts and tables for market impact analysis and drug usage pattern insights.
- Post-launch evaluation and pharmacovigilance capabilities using the OMOP Common Data Model.
- Identification of unmet medical needs for early-stage drug discovery.